Singapore's Scigen to expand local R&D

The Industry, Trade and Labor Ministry announced on Wednesday that the pharmaceutical company Scigen, headquartered in Singapore, intends over the next year to expand its research and development projects in Israel.

By MATTHEW KRIEGER
June 7, 2007 06:59

The Industry, Trade and Labor Ministry announced on Wednesday that the pharmaceutical company Scigen, headquartered in Singapore, intends over the next year to expand its research and development projects in Israel. Scigen manufactures the Hepatitis B vaccine, the main component for which was developed in Israel by Biotechnology General, said Rachel Roei, director of the Ministry's investment promotion center. Scigen, founded in 1988, is one of Singapore's leading bio-pharmaceutical companies and is traded on the Australian Stock Exchange.


Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS